Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Orelabrutinib-Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Treatment of Marginal Zone Lymphoma: A Retrospective Study

He LI, Jiazhuo Liu, Yuhui Chen, Pazilaiti Tuohuti, Yutong Wang, Xinzhu Tang, Bing Xiang, Yongqian Jia, Yu Wu, Yun Tang, Yong Guo, Jie Wang, Yuhuan Zheng, Yu Liu, Ting Niu

Blood (2024) 144 (Supplement 1): 6308.

https://doi.org/10.1182/blood-2024-206464

Published: 2024

Journal Articles

Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort

Blood (2024) 144 (Supplement 1): 982.

https://doi.org/10.1182/blood-2024-194242

Published: 2024

Journal Articles

First-in-Human Phase I/IIa Safety and Efficacy of Flonoltinib Maleate, a New Generation of JAK2/FLT3 Inhibitor in Myelofibrosis

Lijuan Chen, Yongsheng Wang, Jie Wang, Linyu Yang, Ting Niu

Blood (2024) 144 (Supplement 1): 486.

https://doi.org/10.1182/blood-2024-210674

Published: 2024

Journal Articles

Mecapegfilgrastim for Preventing Chemotherapy-Induced Neutropenia in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter, Open-Label, Randomized Controlled Trial

Jie Wang, He LI, Qiaochu Lin, Kun Yang, Chunrong Ma, Hong Zhai, Jin Wei, Yan Zuo, Jie Zhou, Ting Niu

Blood (2024) 144 (Supplement 1): 6498.

https://doi.org/10.1182/blood-2024-206431

Published: 2024

Journal Articles

Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Blood (2024) 144 (Supplement 1): 5044.

https://doi.org/10.1182/blood-2024-211637

Published: 2024

Journal Articles

Clinical Outcomes of EBV-Positive Compared to EBV-Negative Diffuse Large B Cell Lymphoma in the Modern Era

Kristen McClellan, Cheryl Chang, Anivarya Kumar, John Hsu, Samantha M Thomas, Jie Wang

Blood (2024) 144 (Supplement 1): 3088.

https://doi.org/10.1182/blood-2024-198231

Published: 2024

Journal Articles

Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2024-194601

Published: 2024

Journal Articles

Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 1690.

https://doi.org/10.1182/blood-2024-211424

Published: 2024

Journal Articles

3D Live Imaging and Phenotyping of the Subcellular Cytotoxicity in CAR-T Cell Immunotherapy

Liting Chen, Zhaofei Wang, Jie Wang, Jin Jin, Jia Wei, Yicheng Zhang, Peng Fei

Blood (2024) 144 (Supplement 1): 4781.

https://doi.org/10.1182/blood-2024-193597

Published: 2024

Journal Articles

Zanubrutinib Plus R-CHOP (ZR-CHOP) in Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients Who Were Positron Emission Tomography-Positive after Two Cycles of R-CHOP: A Single-Arm, Open-Label, Multicenter Prospective Study

Jie Wang, He Li, Chenlu Yang, Di Wu, Xingli Zou, Tao Yang, Liangliang Ma, Fang Xu, Jie Wang, Minggang Su, Sha Zhao, Lin Ji, Yao Liu, Pengcheng He, Ting Niu

Blood (2024) 144 (Supplement 1): 4488.

https://doi.org/10.1182/blood-2024-193927

Published: 2024

Journal Articles

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

Blood (2023) 142 (Supplement 1): 302.

https://doi.org/10.1182/blood-2023-179304

Published: 2023

Journal Articles

Lymphoma Treatment Alterations in the Context of Autoimmune Disease

Shannon McGue, Andrea Sitlinger, Sophia Chang, Annie Wang, Samantha Thomas, Jie Wang

Blood (2023) 142 (Supplement 1): 4495.

https://doi.org/10.1182/blood-2023-188097

Published: 2023

Journal Articles

Phase 1 Safety and Dose Escalation of Purinostat Mesylate, a Uniquely Potent and Selective Inhibitor of HDAC I and IIb in Relapsed or Refractory Lymphoma and Multiple Myeloma

Jie Wang, He Li, Linyu Yang, Ailin Zhao, Peng Zhao, Jishi Wang, Jin Xiang, Jia Miao, Li Zheng, Yongsheng Wang, Lijuan Chen, Ting Niu

Blood (2022) 140 (Supplement 1): 6612–6613.

https://doi.org/10.1182/blood-2022-167079

Published: 2022

Journal Articles

Clinical Characteristics of Hemophagocytic Lymphohistiocytosis in Adults with Central Nervous System Involvement

Meng Li, Ai-lin Zhao, Lin-feng Li, Xin-ai Gan, Jin-rong Yang, Jie Wang, He Li, Kai Shen, Yun-fan Yang, Ting Niu

Blood (2022) 140 (Supplement 1): 11169.

https://doi.org/10.1182/blood-2022-167106

Published: 2022

Journal Articles

Clinical Significance of Spatial Heterogeneity in Newly Diagnosed and Relapsed Multiple Myeloma

Blood (2021) 138 (Supplement 1): 1607.

https://doi.org/10.1182/blood-2021-152427

Published: 2021

Journal Articles

A Novel Approach for Treatment of T-Cell Malignancies: Targeting T-Cell Receptor Vβ Families

Jie Wang, MDMS, Katarzyna Urbanska, PhD, Prannda Sharma, Mathilde Poussin, Reza Nejati, MD, Lauren Shaw, Megan S. Lim, MD PhD, Stephen J. Schuster, MD, Daniel Powell, Jr., PhD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-142010

Published: 2020

Journal Articles

A Phase 1, Open-Label Study of MGD013, a Bispecific DART ® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jie Wang, MD, Adam S. Asch, MD, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA, Andrew Weickhardt, MBBS(Hons) FRACP DMedSc, Monika Tomaszewska-Kiecana, Monika Dlugosz-Danecka, MD PhD, Halyna Pylypenko, MD, Shakeela Bahadur, MD, Susanna Ulahannan, MD MMed, Janine Koucheki, Jichao Sun, PhD, Hua Li, Francine Chen, MD, Xiaoyu Zhang, John Muth, MS, Patrick Kaminker, PhD, Paul Moore, PhD, Bradley James Sumrow, MD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-139868

Published: 2020

Journal Articles

Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-142622

Published: 2020

Journal Articles

Targeting the Glucagon Receptor Signaling Pathway As a Novel Strategy to Counteract PI3K Inhibitor Induced Hyperglycemia While Sustaining Tumor PI3K Inhibition

Jie Wang, MDMS, Michael Morse, MD, Frank Calzone, Hai Yan, Zung Thai, Takuya Osada, MDPhD, Herbert Lyerly, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140576

Published: 2020

Journal Articles

Tumor Antigen Vaccination of Donors to Augment Graft-Versus-Tumor Effects after Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide

Han-Hsuan Fu, PhD, Jie Wang, MD, Jie Fu, MS, Richard J Jones, MD, Hyam Levitsky, MD, Ephraim J. Fuchs, MD

Blood (2016) 128 (22): 499.

https://doi.org/10.1182/blood.V128.22.499.499

Published: 2016

NARROW

Orelabrutinib-Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Treatment of Marginal Zone Lymphoma: A Retrospective Study

Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort

First-in-Human Phase I/IIa Safety and Efficacy of Flonoltinib Maleate, a New Generation of JAK2/FLT3 Inhibitor in Myelofibrosis

Mecapegfilgrastim for Preventing Chemotherapy-Induced Neutropenia in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter, Open-Label, Randomized Controlled Trial

Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Clinical Outcomes of EBV-Positive Compared to EBV-Negative Diffuse Large B Cell Lymphoma in the Modern Era

Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study

3D Live Imaging and Phenotyping of the Subcellular Cytotoxicity in CAR-T Cell Immunotherapy

Zanubrutinib Plus R-CHOP (ZR-CHOP) in Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients Who Were Positron Emission Tomography-Positive after Two Cycles of R-CHOP: A Single-Arm, Open-Label, Multicenter Prospective Study

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

Lymphoma Treatment Alterations in the Context of Autoimmune Disease

Phase 1 Safety and Dose Escalation of Purinostat Mesylate, a Uniquely Potent and Selective Inhibitor of HDAC I and IIb in Relapsed or Refractory Lymphoma and Multiple Myeloma

Clinical Characteristics of Hemophagocytic Lymphohistiocytosis in Adults with Central Nervous System Involvement

Clinical Significance of Spatial Heterogeneity in Newly Diagnosed and Relapsed Multiple Myeloma

A Novel Approach for Treatment of T-Cell Malignancies: Targeting T-Cell Receptor Vβ Families

A Phase 1, Open-Label Study of MGD013, a Bispecific DART ® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma

Targeting the Glucagon Receptor Signaling Pathway As a Novel Strategy to Counteract PI3K Inhibitor Induced Hyperglycemia While Sustaining Tumor PI3K Inhibition

Tumor Antigen Vaccination of Donors to Augment Graft-Versus-Tumor Effects after Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only